AC Immune to Present at the Jefferies 2018 London Healthcare Conference
November 12 2018 - 4:01AM
Lausanne, Switzerland, November 12, 2018
- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage
biopharmaceutical company with a broad pipeline focused on
neurodegenerative diseases, today announced that it will present at
the Jefferies 2018 London Healthcare Conference in London, UK,
taking place November 14 to 15, 2018.
Jefferies 2018 London Healthcare
ConferenceDate: November 15, 2018 | 12:40 pm GMT Presenter:
Prof. Andrea Pfeifer, CEO, AC Immune
A webcast of the presentation will be available
on the Investor Page of AC Immune's investor page and at the
Jefferies 2018 Healthcare Conference website and will be active for
90 days following the event.
About AC Immune AC Immune is a
clinical-stage Swiss-based biopharmaceutical company, listed on
NASDAQ, which aims to become a global leader in precision medicine
for neurodegenerative diseases. The Company designs, discovers and
develops therapeutic as well as diagnostic products intended to
prevent and modify diseases caused by misfolding proteins. AC
Immune's two proprietary technology platforms create antibodies,
small molecules and vaccines designed to address a broad spectrum
of neurodegenerative indications, such as Alzheimer's disease (AD).
The Company's pipeline features nine therapeutic and three
diagnostic product candidates - with five product candidates
currently in clinical trials. The most advanced of these is
crenezumab, a humanized anti-amyloid-ß monoclonal IgG4 antibody
that targets monomeric and aggregated forms of amyloid-ß, with
highest affinity for neurotoxic oligomers. Crenezumab is currently
in two Phase 3 clinical studies for AD, under a global program
conducted by the collaboration partner Roche/Genentech. Other
collaborations include Biogen, Janssen Pharmaceuticals, Nestlé
Institute of Health Sciences, Life Molecular Imaging (formerly
Piramal Imaging) and Essex Bio-Technology.
Forward looking statements This press
release contains statements that constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements are statements other than historical
fact and may include statements that address future operating,
financial or business performance or AC Immune's strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may," "might," "will," "should,"
"expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "outlook" or "continue," and
other comparable terminology. Forward-looking statements are based
on management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include those described under the captions "Item 3.
Key Information-Risk Factors" and "Item 5. Operating and Financial
Review and Prospects" in AC Immune's Annual Report on Form 20-F and
other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made,
and AC Immune does not undertake any obligation to update them in
light of new information, future developments or otherwise, except
as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
For further information, please
contact:
In EuropeBeatrix BenzAC Immune Corporate Communications
Phone: +41 21 345 91 34E-mail: beatrix.benz@acimmune.com |
In the USLisa SherAC Immune Investor RelationsPhone: +1 970
987 26 54E-mail: lisa.sher@acimmune.com |
Nick Miles/Toomas KullCabinet Privé de Conseils s.a.Phone: +41 22
552 46 46 E-mail: miles@cpc-pr.com kull@cpc-pr.com |
Ted AgneThe Communications Strategy Group Inc.Phone: +1 781 631
3117E-mail: edagne@comstratgroup.com |
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Aug 2024 to Sep 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Sep 2023 to Sep 2024